GlassScriptPhysician profile
Shwetha Anand
NPI 1700079035
$10,408.56
in general payments reported to CMS, 2019-2025
64 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,356 · 2020: $1,199 · 2021: $1,032 · 2022: $868 · 2023: $1,326 · 2024: $1,424 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932 · Entertainment: $21.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.28 |
| Entertainment | $21.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,433.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,264.37 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Lilly USA, LLC | $909.41 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $723.32 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $682.13 | 2019-2025 | Jardiance, Gilotrif |
| Janssen Pharmaceuticals, INC | $336.65 | 2019-2020 | |
| Amgen INC. | $312.55 | 2019-2025 | Tepezza, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $306.50 | 2022-2025 | |
| Janssen Biotech, INC. | $277.62 | 2022-2025 | Darzalex, Imbruvica, Rybrevant |
| Sanofi-Aventis U.S. LLC | $261.65 | 2019-2025 | |
| Mannkind Corporation | $246.88 | 2019-2025 | Afrezza |
| Radius Health, INC. | $235.48 | 2019-2025 | |
| Amarin Pharma, INC. | $212.68 | 2019-2020 | |
| Medtronic Minimed, INC. | $200.25 | 2019 | |
| Abbott Laboratories | $160.37 | 2022-2025 | Freestyle Libre 3 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $159.72 | 2019-2025 | Libtayo |
| Medtronic, INC. | $156.46 | 2021-2025 | Minimed 780g |
| Abbvie INC. | $149.51 | 2019-2025 | |
| Genentech USA, INC. | $145.26 | 2023-2025 | Tecentriq, Tecentriq Hybreza, Avastin |
| Dexcom, INC. | $140.34 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $132.85 | 2019-2025 | Ninlaro, Iclusig |
| Corcept Therapeutics | $132.07 | 2019-2021 | |
| Insulet Corporation | $123.30 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $94.14 | 2023-2025 | Monoferric |
| Coherus Oncology, INC. | $91.25 | 2023-2024 | |
| Glaxosmithkline, LLC. | $85.88 | 2022-2023 | Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $76.26 | 2024-2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $70.51 | 2020-2024 | Ultomiris, Strensiq |
| Daiichi Sankyo INC. | $69.89 | 2023-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $68.66 | 2025 | |
| Pfizer INC. | $66.95 | 2023-2024 | |
| Blueprint Medicines Corporation | $59.95 | 2025 | Ayvakit |
| Astellas Pharma US INC | $57.47 | 2024 | Veozah |
| Kyowa Kirin, INC. | $56.12 | 2024 | Crysvita |
| Amneal Pharmaceuticals LLC | $54.81 | 2024-2025 | Alymsys, Neulasta, Avastin |
| Stemline Therapeutics INC. | $54.00 | 2025 | Orserdu |
| Ascendis Pharma Endocrinology INC | $49.96 | 2025 | Yorvipath |
| Beta Bionics, INC. | $48.13 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tempus Ai, INC | $46.71 | 2025 | Xt Cdx |
| Adc Therapeutics America, INC. | $42.88 | 2024 | |
| Azurity Pharmaceuticals, INC. | $41.41 | 2024-2025 | Vivimusta, Danziten |
| Pharmacyclics LLC, An Abbvie Company | $39.79 | 2019-2023 | Imbruvica |
| Beigene USA, INC. | $38.55 | 2024-2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $33.14 | 2025 | Pyrukynd |
| Madrigal Pharmaceuticals | $32.51 | 2025 | Rezdiffra |
| Beone Medicines USA, INC. | $31.42 | 2025 | Brukinsa |
| Tandem Diabetes Care, INC. | $29.45 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $29.07 | 2025 | |
| Sobi, INC | $27.68 | 2025 | |
| Genmab U.S., INC. | $26.44 | 2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $26.07 | 2025 | |
| Pharmaessentia USA Corporation | $25.65 | 2025 | Besremi |
| Tactile Systems Technology INC | $22.19 | 2023 | Flexitouch Plus, Entre Plus |
| Optos, INC. | $21.38 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Progenics Pharmaceuticals, INC. | $21.03 | 2024 | |
| Iovance Biotherapeutics, INC. | $20.78 | 2025 | Amtagvi |
| Hikma Pharmaceuticals USA | $20.36 | 2019 | |
| Shire North American Group INC | $19.08 | 2019 | |
| Legend Biotech USA INC. | $18.73 | 2025 | Carvykti |
| Fresenius Kabi USA, LLC | $18.55 | 2025 | Stimufend |
| Irhythm Technologies, INC. | $18.40 | 2020 | |
| Cequr Corporation | $18.27 | 2023 | Cequr Simplicity |
| Sanofi Pasteur INC. | $17.43 | 2019 | |
| Almatica Pharma LLC | $14.54 | 2025 | Teriparatide, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shwetha Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.